NCT00003533View on ClinicalTrials.gov

Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 27, 1996

Primary Completion Date

December 31, 1999

Study Completion Date

December 31, 1999

Conditions
Metastatic Prostate Cancer
Interventions
DRUG

Antineoplaston therapy (Atengenal + Astugenal)

"Patients with Metastatic Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."

Trial Locations (1)

77055-6330

Burzynski Clinic, Houston

Sponsors
All Listed Sponsors
lead

Burzynski Research Institute

OTHER